Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Epidiolex May Have Avoided CRL Over Metabolite Assessment Due To Unmet Need

Sep 26 2018

• By Michael Cipriano

Related Content

Sickle Cell Disease Treatment Gets Panel Nod Despite Efficacy Concerns

May 25 2017

Unmet Need Can Trump Anything At US FDA Panels, Even An Ill-Prepared Sponsor

May 31 2017

Epidiolex Advisory Committee Appears To Be Covering US FDA's Bases, But Liver Injury Concerns Persist

Apr 17 2018

Epidiolex Enjoys Mellow Advisory Cmte. Meeting

Apr 20 2018

Gottlieb: Epidiolex Approval Covers One Specific Cannabidiol Medication, Not Marijuana

Jun 25 2018

Epidiolex Reviewers

Sep 26 2018

Epidiolex Clinical Review Timeline

Sep 26 2018

Epidiolex Almost Didn't Get Proprietary Name Because Of Confusion With OTC Pedia-Lax

Sep 26 2018

ODE-1 Director Unger, Not Medical Officer, Conducted Epidiolex Safety Review

Sep 26 2018

Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?

Sep 21 2016

Related Companies

Emmaus Life Sciences, Inc.

Sarepta Therapeutics, Inc.

Additional Topics

United States Regulation Drug Review Profile Neurology BioPharmaceutical

More from Drug Review Profiles

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window